EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 25 / Numéro 10 (Octobre 2009) Med Sci (Paris), 25 10 (2009) 785-788 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 25, Numéro 10, Octobre 2009
Page(s) 785 - 788
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20092510785
Publié en ligne 15 octobre 2009
  1. Huntly BJ, Shigematsu H, Deguchi K, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004; 6 : 587–96. [Google Scholar]
  2. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 8 : 8. [Google Scholar]
  3. Frohling S, Dohner H. Chromosomal abnormalities in cancer. N Engl J Med 2008; 359 : 722–34. [Google Scholar]
  4. Nimer SD. Myelodysplastic syndromes. Blood 2008; 111 : 4841–51. [Google Scholar]
  5. Vainchenker W, Dusa A, Constantinescu SN. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol 2008; 19 : 385–93. [Google Scholar]
  6. Kralovics R. Genetic complexity of myeloproliferative neoplasms. Leukemia 2008; 22 : 1841–8. [Google Scholar]
  7. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360 : 2289–301. [Google Scholar]
  8. Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009; 23 : 900–4. [Google Scholar]
  9. Tefferi A, Lim KH, Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009; 23 : 1343–5. [Google Scholar]
  10. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009; 23 : 905–11. [Google Scholar]
  11. Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009; 114 : 144–7. [Google Scholar]
  12. Gelsi-Boyer V, Trouplin V, Adelaide J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 13 : 13. [Google Scholar]
  13. Jankowska AM, Szpurka H, Tiu RV, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009; 113 : 6403–10. [Google Scholar]
  14. Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41 : 838–42. [Google Scholar]
  15. Lorsbach RB, Moore J, Mathew S, et al. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 2003; 17 : 637–41. [Google Scholar]
  16. Ono R, Taki T, Taketani T, et al. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res 2002; 62 : 4075–80. [Google Scholar]
  17. Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009; 324 : 930–5. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.